Earnings Season Shows Mixed Results for Major Companies

Earnings season provides key insights into companies' performances. Major players like Eli Lilly and AbbVie missed earnings but showed revenue growth, keeping investors optimistic.

Date: 12-02-2025

AI Rating: 6

Earnings Per Share (EPS): Eli Lilly reported an EPS of $5.32, missing expectations by 13 cents, while AbbVie posted an EPS of $2.16, falling short of estimates by 82 cents and 30% lower YOY.

Revenue Growth: Eli Lilly's revenue of $13.53 billion beat expectations of $13.43 billion, driven by a 60% increase in Mounjaro sales. AbbVie also exceeded revenue expectations at $15.10 billion compared to the estimated $14.83 billion.

General Outlook: Despite earnings misses, analyst forecasts and strong revenue growth in both companies signal potential for future investments. The consensus price target for Eli Lilly stands at $997.50 (13.6% upside), and AbbVie has shown resilience beyond its flagship product, Humira.

Consumer Discretionary Stocks: Las Vegas Sands reported revenues of $2.9 billion, surpassing expectations but were flat YOY. While it missed EPS by four cents, there’s optimism based on its plans for expansion and potential revenue increases in Macao.

Stocks: LLY ABBV LVS